autologous cd34 hscs transduced ex vivo with cd11b lv encoding human ids tagged with apoeii
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05665166)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05665166 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2023 | AvroBio, CTI Clinical Trial and Consulting Services, LifeArc, University of London, University of Manchester |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AvroBio | For profit | 1 | 0 | 1 | 2023 |
| CTI Clinical Trial and Consulting Services | For profit | 1 | 0 | 1 | 2023 |
| LifeArc | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Manchester | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1